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Thioredoxin reductase 1 (TRXR1) and microsomal glutathione transferase 1 (MGST1) are important
redox and detoxifying enzymes in adult life. The aim of this study was to investigate the expression
of these enzymes during fetal life. In addition, the role of gene methylation was studied since this
might play an important role in the on-and-off switch of gene expression between fetal and adult
life.
To this end, the expression of the TRXR1-encoding gene TXNRD1 and the MGST1-encoding gene
MGST1 was studied in fetal tissues. The mean mRNA expression of TXNRD1 in fetal livers were seven
times higher compared to the mean expression in adult livers (p < 0.001). Of the six studied splice
variants of TXNRD1, four had a signiﬁcantly higher expression in the fetal livers as compared to
adult livers. The mean expression of MGST1 was twofold higher in adult compared to fetal liver
tissue (p = 0.01). For MGST1 the alternative ﬁrst exon 1B was the predominant splice variant in both
fetal and adult liver samples. The highest mRNA expression of both TXNRD1 andMGST1was found in
fetal adrenals, whereas expression was lower in fetal liver, lungs and kidneys. There was a
signiﬁcant correlation between the hepatic expression of TXNRD1 and MGST1. Treatment with the
demethylating agent 5-AZA resulted in decreased levels of TXNRD1 in human liver HepG2 cells
but did not affect the expression of MGST1.
In conclusion, the expression of TXNRD1 is higher in fetuses than in adults and might be of
importance during fetal life. Hepatic TXNRD1 andMGST1 are co-expressed in both fetuses and adults
suggesting common regulatory mechanisms.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction involved in many cellular processes including redox control ofThioredoxin reductase 1 (TRXR1) and microsomal glutathione
transferase 1 (MGST1) are important enzymes for redox control
and detoxiﬁcation during adult life. Animal studies have shown
that TRXR1 is important also in fetal life [1,2] but it has never been
investigated in human fetal tissue. The aim of this study was to
investigate the expression of TRXR1 and MGST1 in human fetal tis-
sues and compare with the expression in adult liver.
The mammalian thioredoxin system consists of thioredoxin,
thioredoxin reductase (TRXR) and NADPH [3]. This system istranscription factors, reduction of peroxides, regulation of apopto-
sis and synthesis of deoxyribonucleotides [4]. Mammalian TRXRs
are selenocysteine-containing oxidoreductase ﬂavoproteins with
remarkable broad substrate speciﬁcity [4]. Three different human
genes that encode TRXR enzymes have been identiﬁed; the classi-
cal cytosolic TRXR1, the mitochondrial TRXR2 and the mitochon-
drial TRXR3 (also known as TGR) mainly expressed in the testis [4].
The TRXR1 encoding gene TXNRD1 is widely expressed and is
up-regulated by various stimuli such IL-1B, lipopolysaccharide,
epidermal growth factors and hydrogen peroxide [4], whereas for
example statins have been shown to inhibit the transcription of
TXNRD1 [5]. However, the mechanisms of these transcriptional reg-
ulations remain unclear. In fact the transcriptional regulation of
TXNRD1 is complex and involves several mechanisms such as alter-
native splicing and different transcriptional start sites [6]. In
humans, 21 different mRNA forms have been identiﬁed, all differ-
ing in the 50-end [7]. A putative CpG island in the TXNRD1 promoter
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the CpG sites has not been studied.
TRXR1 has been shown to be essential for embryonic develop-
ment. Txnrd/ mice resulted in early embryonic death between
days 9.5 and 10.5, with a defect in cell proliferation and severe
growth retardation [1]. Jurado et al. noted that Txnrd1 expression
peaked around week 10 in mice. Interestingly the Txnrd1 level
was 6-fold higher early in the mouse embryo compared to adult
organs [2]. Even though it is known that TRXR1 is essential in
the embryonic stage of mice, little is known about the ontogeny
of TXNRD1 expression in humans.
MGST1 is an enzyme that exerts both glutathione transferase
activity as well as reduction of various hydroperoxides, being
important in the protection against oxidative stress [9]. The
expression of the MGST1 encoding gene MGST1 is abundant in
most tissues, with the highest gene expression levels found in liver
and pancreas [10]. Several alternative ﬁrst noncoding exons have
been identiﬁed, whereas one is predominantly expressed in the
liver [10,11]. The ontogeny expression of MGST1 in humans has
never been studied, but it is well known that cytosolic GSTs are
functional in various human fetal tissues [12–14].
The speciﬁc aims of this study were to measure and compare
the gene expression of TXNRD1 andMGST1 in adult and fetal livers,
and to study the intra-individual gene expression proﬁle of
TXNRD1 and MGST1 in fetal livers, lungs, adrenals and kidneys.
We also chose to co-investigate the gene expression and ontoge-
netic of TXNRD1 and MGST1 to investigate whether common
regulatory mechanisms were involved. Moreover the effect of 5-
AZA-2-deoxyxytidine (5-AZA), a demethylating agent, on TXNRD1
and MGST1 gene expression was studied in HepG2 cells since
methylation plays an important role in the on-and-off switch of
gene expression between fetal and adult life.
2. Materials and methods
2.1. Fetal and adult liver samples
Human adult liver specimens from 20 subjects were collected
from a human donor liver bank established at the Division of
Clinical Pharmacology, Karolinska University Hospital, as previ-
ously described [15]. Human fetal specimens from liver (N = 60),
adrenal (N = 46), kidney (N = 43) and lung (N = 37) from 60 fetuses
were obtained at legal abortions which were performed for socio-
medical reasons at the Karolinska university hospital between year
2000 and 2003. The fetal tissues were excised and immediately
frozen in liquid nitrogen and stored at 70 within 2 h. The study
was approved by the regional Ethics committee in Stockholm
and by the National Board of Health and Welfare.
The gestational ages were determined by crown-rump length
and ranged from 5 to 12 weeks (median age 10.2). The maternal
age ranged from 18 to 43 years (median 29 years). None of the
women reported any chronic or acute disease, regular drug use,
or drug abuse. Smoking was reported in 22 women (37%), non
smoking in 21 (35%), whereas for 17 there were no reports.
2.2. RNA preparations and real time PCR
Total RNA from 5 to 30 mg of fetal tissue samples and approx-
imately 200 mg of adult liver tissues was prepared using Allprep
DNA/RNA and RNAeasy kit (Qiagen), respectively. RNA concentra-
tion and quality were determined using a spectrophotometer
(NanoDrop Technologies, Wilmington, DE) and all the RNA samples
displayed a 260/280 ratio between 1.6 and 2.1.RNA (0.5 lg) was reverse transcribed into cDNA with hexamer
primer using Superscript III (Invitrogen) according to the manufac-
turer´s protocol and diluted ten times.
The relative mRNA level of TXNRD1 in liver tissues was
determined by real-time PCR using the 7500 Fast System (Applied
Biosystems). 18S (# 4310893E Applied Biosystems) was chosen as
endogenous housekeeping control gene. For total TXNRD1 and
MGST1 analysis reaction mix Hs00182418_ml or Hs00220393_m1
(Applied Biosystems) and 2 Taqman reaction mix (Applied Bio-
systems) were used. For analysis of different TRXR1 and MGST1
isoforms the reactions contained 2 SYBR green reaction mix
(Applied Biosystems, Foster City, CA) and 450 mmol of a1/2, a6,
a7/8, a10/11, a13, c2–4 primers for TRXR1 splice variants
(sequences described in [16]), and 1A, 1B, 1C, 1D exon speciﬁc
MGST1 primers (sequences described in [11]). All the reactions
included 1 ll cDNA template in a total volume of 15 ll. Thermal
cycling conditions included activation at 95 C (10 min) followed
by 40 cycles each of denaturation at 95 C (15 s) and annealing/
elongation at 60 C (1 min). Each reaction was performed in dupli-
cates and no-template controls were included in each experiment.
For the comparison between the mRNA expression in adult and
fetal liver samples, an adult liver sample was employed as a cali-
brator and the delta CT-formula was used as described [17]. For
intra-individual comparison between fetal tissues, a fetal liver
sample was used as a calibrator. When different splice variants
were compared, the TRXR1 a1/2 and MGST1 1B were chosen as
calibrators, respectively.
2.3. Cell culture
Human liver cancer HepG2 cells were cultured in MEM supple-
mented with 5% FCS, 1% penicillin/streptomycin, 1% L-glutamine
and maintained in humidiﬁed atmosphere at 37 C and 5% CO2.
No additional selenium source above that present in 5% FCS was
added and the cells were thereby selenium starved but not
selenium deﬁcient [18]. Prior to 5-AZA exposure the HepG2 cells
were split and plated in 12-well plates and pre-incubated for
2 days. 5-AZA were diluted in DMSO and added to the cells for
24 h at ﬁnal concentration 5 mM. The non-treated controls were
incubated with vehicle only. The experiments were performed in
four independent experiments. The cells were harvested with Tri-
zol (Invitrogen, UK) and RNA was extracted according the protocol
and kept at 80 C.
2.4. Statistical analysis
To investigate if there was any signiﬁcant difference in relative
hepatic expression between two groups (adult–fetal, smoking–
non-smoking, 5-AZA-control) the nonparametric Mann–Whitney
test was used since the measurements were few and could not
be proven to be normally distributed. When looking for signiﬁcant
difference in splice variants and in tissue-speciﬁc (livers, kidneys,
adrenals, lungs) expression of TXNRD1 and MGST1 the nonpara-
metric Kruskal–Wallis test was performed followed by Dunn’s
multiple comparison post-test for identiﬁcation of which groups
differed from the other. The results are presented as mean ± SEM
and in box and whisker plots, i.e. the bottom and top of the box
are the ﬁrst and third quartiles, and the band inside the box is
the median. The ends of the whiskers represent the 5–95th percen-
tile. The correlation analyses were performed by the Spearman
rank method. All statistical tests were performed using GraphPad
Prism v. 5.00 and values of p < 0.05 were considered statistically
signiﬁcant.
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3.1. The mRNA expression of total TXNRD1 and MGST1 in adult and
fetal liver
In order to compare the TXNRD1 mRNA expression between
adult and fetal liver samples we used primers that bind to exon
5 and exon 6. TXNRD1 was detectable in 59 of 60 fetal and 17 of
20 adult liver samples. Signiﬁcantly higher levels of TXNRD1mRNA
transcripts were observed in the fetal liver samples as compared to
the adult liver samples. The mean TXNRD1 was 7 times higher in
fetal liver compared to adult liver (mean 12.8 ± 0.82 vs mean
1.82 ± 0.48; p < 0.0001) as shown in Fig. 1. In the adults specimens
a larger inter-individual variation in TXNRD1mRNAwas found (90-
fold) compared to the fetal specimens in which a 30-fold variation
was found.
MGST1 was detectable in 59 (98%) and 18 (90%) of the fetus and
adult samples investigated. There was a 2-fold higher expression of
MGST1 in adults as compared to fetal expression (p = 0.01) (Fig. 1).
A large (30-fold) inter-individual variation of MGST1 gene expres-
sions were noted both in adults and fetuses.
3.2. The mRNA expression proﬁle of six TRXR1 splice variants in fetuses
Several isoforms of TRXR1 have been identiﬁed. Here we have
studied the abundance of six splice variants previously described
[16]. Of these, four splice variants (a1/2, a6, a7/8, and a10/11)
were signiﬁcantly higher in the fetal livers as compared to adult
livers. The mean relative mRNA levels (±SEM) in fetal comparedFig. 1. Relative mRNA expression of TXNRD1 and MGST1 mRNA in 59 fetal and 17
adult liver tissue samples. There was a 7-fold higher expression of TXNRD1 in fetal
than adult liver tissue (p < 0.001). In contrast, there was a 2-fold higher expression
of MGST1 in adult compared to fetal liver tissue (p = 0.01). Statistical analyses were
performed using Mann–Whitney test.to adult livers were 21 ± 1 and 2.4 ± 0.66 for a1/2, 37 ± 2.4 and
1.4 ± 0.36 for a6, 15 ± 0.86 and 0.79 ± 0.10 for a7/8, 22 ± 1.6 and
1.0 ± 0.1 for a10/11 respectively.
All the six splice variants were frequently abundant in the fetal
samples. a1/2, a6, a7/8, a10/11, a13 and c2–4, were detected in
98%, 97%, 92%, 97%, 93% and 97% of the samples, respectively. In
the adult samples however, occurrence of the splice variants was
only observed in 65%, 40%, 90%, 20%, 60% and 25% of the samples
analyzed.
In fetal liver samples a7/8 was the most abundant transcript,
three times higher than the wildtype a1/2 (p < 0.001), whereas
the isoforms a13 and c2–4 were found at lowest levels (Fig. 2).
In the adult liver samples a13 was found at the highest levels,
but with a large inter-subject variation (200-fold). Isoform a6
was present at the lowest levels compared to the other isoforms
(Fig. 2).
3.3. The mRNA expression proﬁle of MGST1 splice variants
MGST1 1B and MGST1 1D were found in 93% and 88% of the
fetal samples and in 70% and 60% of the adult liver samples inves-
tigated. Both in the fetal and adult liver samples the alternative
ﬁrst exon 1B was the predominant variant, the mean expressionFig. 2. Relative mRNA expression of 6 different splice variants of TXNRD1. In fetal
liver samples (N = 59) a7/8 was the most abundant transcript, and signiﬁcantly
higher than the other variants (p < 0.001). In the adult liver samples (N = 17) a13
was found at high levels in some but not in all samples, i.e. there was a large inter-
subject variation. The average expressions of a7/8 and a1/2 were signiﬁcantly
higher compared to a6 and a10/11. Statistical analysis were performed using
Kruskal–Wallis test followed by Dunn’s multiple comparison post-test for identi-
ﬁcation of which groups differed from the other.
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respectively. There was no difference in the expression of MGST1
1B transcript between adults (mean 1.84 ± 0.58) and fetuses (mean
1.59 ± 0.24), whereas MGST1 transcript including the alternative
exon 1D was 5-fold higher in adults (mean 4.92 ± 1.7) as compared
to fetuses (mean 1.06 ± 0.13; p = 0.0006). The other putative
alternative exons 1 (1A and 1C) were not identiﬁed in any sample,
further supporting that these exons are non-expressed.
3.4. Expression of TRXR1 and MGST1 in different fetal tissue
TXNRD1 and MGST1 transcripts were abundant in all adrenals,
kidney and lung samples analyzed. There was no correlation
between the extra-hepatic expressions of these genes. The highest
mRNA expression of TXNRD1 was found in the adrenals whereas
the liver, lungs and kidney had lower and about equal expression.
For MGST1 also the adrenals had the highest expression, followed
by the liver whereas the lowest expression was found in lungs
and kidneys (Fig. 3).
3.5. Correlation between hepatic TXNRD1 and MGST1 mRNA
expression
There was a signiﬁcant correlation between hepatic TXNRD1
and MGST1 mRNA levels in both the fetuses (r = 0.49, p < 0.0001)
and adult samples (r = 0.60, p = 0.01) (Fig. 4).
There was no correlation between the fetal gestational age and
the mRNA expression of TXNRD1 or MGST1 in any specimens stud-
ied. Moreover, there was no apparent effect of maternal smokingFig. 3. Relative mRNA expression of TXNRD1 and MGST1 in different fetal tissues;
liver (N = 59), adrenal (N = 46), kidney (N = 43) and lung (N = 37). TXNRD1 had a
signiﬁcantly higher expression in adrenal tissue compared to the other tissues
(p < 0.001). MGST1 had a signiﬁcantly higher expression in adrenal and liver tissue
compared to kidney and lung tissue (p < 0.001). Statistical analysis were performed
using Kruskal–Wallis test followed by Dunn’s multiple comparison post-test for
identiﬁcation of which groups differed from the other.
Fig. 4. Correlation analyses between the relative mRNA expression of TXNRD1 and
MGST1 in fetal (N = 59) and adult (N = 17) liver tissue were performed using
Spearman rank method. There was a signiﬁcant correlation between hepatic
TXNRD1 and MGST1 mRNA levels in both fetal (r = 0.49, p < 0.0001) and adult liver
tissue (r = 0.60, p = 0.01).on the gene expression of TXNRD1 and MGST1 in fetal liver (data
not shown).
3.6. Methylation in HepG2 cells
HepG2 cells were treated with 5 mM 5-AZA and analyzed for
the gene expression of TXNRD1 and MGST1 and were performed
in four independent experiments. The mRNA expression of TXNRD1
was inhibited in every experiment and in average by 34% by the
exposure of 5-AZA in the HepG2 cells (p = 0.03), whereas 5-AZA
did not affect the expression of MGST1 (data not shown).
4. Discussion
This is the ﬁrst time the expression proﬁle of both MGST1 and
TXNRD1 has been studied in human fetal samples. Both genes were
highly expressed in the ﬁrst trimester. TXNRD1mRNA was found at
7-fold higher levels in fetal than in adult livers. This is in agree-
ment with previous studies performed in mice where embryos
expressed higher levels of Txnrd1 compared to adults [2]. Our
results, i.e. that TXNRD1 is highly abundant and consistently found
in human fetuses indicates that TRXR1 is an important enzyme
during human embryonic fetal development.
In contrast to TXNRD1, but in agreement with several other
phase II drug metabolizing enzymes, MGST1 transcripts seems to
be more abundant in adults than in fetuses. This is in line with pre-
vious result showing that Mgst1 mRNA expression was detected
prenatally (2 days before birth) and increased with age in newborn
mice [19]. Moreover, the GST activity has been shown to be higher
in cytosolic liver human samples obtained from adults as
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for microsomal GST activity in the rat [21].
Here we show for the ﬁrst time that mRNAs speciﬁc for TXNRD1
and MGST1 are correlated in the liver, both in fetuses and adults.
The reason for this correlation is not known, but the genes share
some common transcriptional regulatory mechanisms. Both genes
comprises functional Sp1 sites in their proximal promoter regions
[8,19]. Both MGST1 and TXNRD1 genes also display elements for
Oct-4, a transcription factor known to drive the gene expression
in early embryogenesis [22]. So this may be a putative factor for
high correlation observed in the ﬁrst trimester. Future studies are
warranted to further understand how these genes are co-regulated
in different settings.
We did not note any correlation between gestational age and
expression level. However, all our samples were collected during
the ﬁrst trimester. It is possible that the expression proﬁle of
TXNRD1 and/or MGST1 is altered during fetal development. Unfor-
tunately, sex was not determined at the collection of fetus
specimens.
As in the case of TXNRD1 andMGST1, the mRNA expression pro-
ﬁle during the development is often different than in adults. This
developmental switch may be driven by different transcriptional
mechanisms such as alternative splicing. Here we noted different
distribution of the TXNRD1 isoforms between adults and fetuses,
indicating that there may be some switches in the splicing events
during ontogeny. Most splice variants investigated here were
found at higher levels in the fetal liver samples. a7/8 was the pre-
dominant isoform during ﬁrst trimester. The same splicing proﬁle
has been reported in adult malignant mesothelioma cells, where
a1/2 and a7/8 were the major transcripts, whereas a6 was found
at the lowest levels [16]. For MGST1, our results indicate that the
alternative ﬁrst exon 1B is preferred in both fetuses and adults.
This is in agreement with previous ﬁndings [10,11]. This ﬁrst exon
is the exon that gives rise to the predominant mature mRNA tran-
scripts in human tissues [10].
In addition to TXNRD1 and MGST1 gene expression in livers, we
performed studies in fetal samples obtained from adrenals, kidneys
and lungs. The expression of TXNRD1 was most pronounced in the
adrenal tissue suggesting an important role for the enzyme in this
tissue during fetal life. To our knowledge a comparison of the
expression of TRXR1 in different tissues in adults has not been
done. MGST1 was most abundant in adrenals and livers during
the ﬁrst trimester. In adults MGST1 transcripts have been found
at highest levels in livers and pancreas [10].
Epigenetic events such as DNAmethylation of CpG sites has been
suggested to play a role in the developmental switch in gene expres-
sion of several genes [22,23]. Methylation of CpG islandsmay result
in inhibition of transcriptional rate or in some cases activation. Even
though a CpG islandwas identiﬁed in silico in the proximal promoter
of TXNRD1, no one has investigated the methylation grade of the
TXNRD1 promoter in vivo. Our 5-AZA results indicate that methyla-
tion of TXNRD1 may be a transcriptional determinant in liver cells.
We showed that de-methylation leads to decrease in TXNRD1
expression in HepG2 cells. Even though up-regulation is more com-
mon, several genes have been shown to be repressed by 5-AZA
exposure in HepG2 cells [24]. It is possible that de-methylation
increases access of repressor binding sites. Alternatively, the avail-
ability of trans-active factors may decrease. It would be of interest
to further assess the CpG island in TXNRD1 and study whether or
not the methylation grade differs throughout development.
MGST1 expression was not affected by 5-AZA indicating that
DNA methylation does not play an important role in MGST gene
expression, at least not in HepG2 cells. This is consistent with an
in silico analysis using UCSC Genome Bioinformatics (www.
http://genome-euro.ucsc.edu/index.html), which did not identify
any CpG islands in the MGST1 gene.Many proteins that are highly expressed during fetal life are
often overexpressed also in malignant cells. Such proteins can be
used as biomarkers for different types of cancer, for example
alfa-fetoprotein that is a biomarker for liver cancer. TRXR1 is over-
expressed in many cancer cells and plays an important role during
carcinogenesis [25–27]. This is in accordance with the results pre-
sented here showing high expression of TRXR1 during fetal life.
Indeed, it has been discussed whether this enzyme could be used
as a biomarker for different cancers [25,28].
In conclusion we have found that the expression of TXNRD1 is
higher in the ﬁrst trimester than in adult life and might be of
importance during fetal life, whereas MGST1 was more abundant
in adults. Interestingly, hepatic TXNRD1 and MGST1 are co-
expressed in the fetuses as well as in adults suggesting common
mechanism for regulation. In addition, DNA methylation may be
important in the regulation of the transcriptional activity of
TXNRD1 but is probably of minor importance for MGST1.Author contributions
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